CL2019003613A1 - Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos. - Google Patents

Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.

Info

Publication number
CL2019003613A1
CL2019003613A1 CL2019003613A CL2019003613A CL2019003613A1 CL 2019003613 A1 CL2019003613 A1 CL 2019003613A1 CL 2019003613 A CL2019003613 A CL 2019003613A CL 2019003613 A CL2019003613 A CL 2019003613A CL 2019003613 A1 CL2019003613 A1 CL 2019003613A1
Authority
CL
Chile
Prior art keywords
antibodies
bispecific antibodies
manufacture
therapeutic use
bispecific
Prior art date
Application number
CL2019003613A
Other languages
English (en)
Inventor
Michael Otto Bardroff
Tina Buch
Christian Graf
Daniel Heitmann
Thomas Jostock
Hans-Peter Knopf
Rolf Koheler
Jiri Kovarik
Stephen John Oliver
Dhavalkumar Patel
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019003613A1 publication Critical patent/CL2019003613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCIÓN SE REFIERE A ANTICUERPOS MONOCLONALES BIESPECÍFICOS BIVALENTES (BBMAB) O SUS VARIANTES, Y A MÉTODOS DE FABRICACIÓN DE DICHOS ANTICUERPOS MEDIANTE LA COEXPRESIÓN DE DERIVADOS MUTADOS FC MODIFICADOS, DE DOS ANTICUERPOS MONOCLONALES DIFERENTES, EN LÍNEAS CELULARES DE MAMÍFEROS.
CL2019003613A 2017-06-12 2019-12-10 Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos. CL2019003613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762518090P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
CL2019003613A1 true CL2019003613A1 (es) 2020-07-03

Family

ID=62948274

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003613A CL2019003613A1 (es) 2017-06-12 2019-12-10 Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.

Country Status (25)

Country Link
US (2) US20190002589A1 (es)
EP (1) EP3638692A1 (es)
JP (2) JP7106234B2 (es)
KR (2) KR20200005746A (es)
CN (1) CN110730788A (es)
AR (1) AR112419A1 (es)
AU (2) AU2018284303B2 (es)
BR (1) BR112019025904A2 (es)
CA (1) CA3061097A1 (es)
CL (1) CL2019003613A1 (es)
CO (1) CO2019013838A2 (es)
CR (1) CR20190558A (es)
CU (1) CU20190100A7 (es)
EA (1) EA201992670A1 (es)
EC (1) ECSP19087580A (es)
IL (1) IL271179A (es)
JO (1) JOP20190283B1 (es)
MA (1) MA49394A (es)
MX (1) MX2019015021A (es)
PE (1) PE20200384A1 (es)
SG (1) SG10201913536TA (es)
TW (1) TWI826377B (es)
UY (1) UY37758A (es)
WO (1) WO2018229612A1 (es)
ZA (1) ZA201906757B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
CN116396393A (zh) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CA3085784A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer driver and controller
CA3098277A1 (en) * 2018-05-09 2019-11-14 Novartis Ag Use of canakinumab
CN111018969A (zh) * 2019-12-27 2020-04-17 上海药明生物技术有限公司 采用轻链select联合层析色谱纯化双特异性抗体的方法
CN115066258A (zh) * 2020-02-28 2022-09-16 上海药明生物技术有限公司 双特异性抗体的纯化
TW202225191A (zh) * 2020-11-04 2022-07-01 美商建南德克公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之皮下給藥
AU2021384022A1 (en) * 2020-11-18 2023-06-01 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
IL308134A (en) 2021-06-22 2023-12-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
CN113980135B (zh) * 2021-12-27 2022-04-19 三优生物医药(上海)有限公司 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用
WO2023209568A1 (en) * 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
KR100254759B1 (ko) 1992-01-23 2000-05-01 플레믹 크리스티안 단량체 및 이량체 항체-단편 융합 단백질
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP3332807B1 (en) 2005-10-26 2023-02-22 Novartis AG Use of anti il-1beta antibodies
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
KR102606597B1 (ko) * 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
CA2709894C (en) 2007-12-21 2017-10-24 Novartis Ag Mammalian expression vector
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
PL2329020T3 (pl) 2008-08-28 2013-08-30 Novartis Ag Prezentacja izoform polipeptydu na powierzchni komórki poprzez nadczytywanie kodonu stop
PT2401377T (pt) 2009-02-27 2016-08-18 Novartis Ag Sistema de vectores de expressão compreendendo dois marcadores de selecção
US8962274B2 (en) 2009-02-27 2015-02-24 Novartis Ag Methods for selecting eukaryotic cells expressing a heterologous protein
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
MX342135B (es) 2011-03-17 2016-09-14 Ramot At Tel-Aviv Univ Ltd Anticuerpos asimetricos, biespecificos y monoespecificos, y metodos para generar los mismos.
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2014052072A1 (en) 2012-09-26 2014-04-03 3M Innovative Properties Company Coatable composition, soil-resistant composition, soil-resistant articles, and methods of making the same
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
MX2015010843A (es) 2013-02-26 2016-04-04 Roche Glycart Ag Moleculas biespecificas de union al antigeno que activan celulas t.
US20140377253A1 (en) * 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
PL3587448T3 (pl) 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
AP2015008656A0 (en) 2013-03-15 2015-08-31 Novartis Ag Antibody drug conjugates
ES2758504T3 (es) 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
CA2934412C (en) 2013-12-20 2024-02-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
GB201414823D0 (en) * 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
KR20170084326A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
KR20230003589A (ko) 2015-03-05 2023-01-06 씽크 써지컬, 인크. 공구 축선을 위치설정 및 추적하기 위한 방법
EP4059514A1 (en) 2015-05-08 2022-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
CN116396393A (zh) * 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
CA3036564A1 (en) * 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos

Also Published As

Publication number Publication date
PE20200384A1 (es) 2020-02-24
US11987644B2 (en) 2024-05-21
UY37758A (es) 2019-01-31
ECSP19087580A (es) 2019-12-27
CN110730788A (zh) 2020-01-24
US20200308309A1 (en) 2020-10-01
CU20190100A7 (es) 2020-11-30
JP7106234B2 (ja) 2022-07-26
RU2019140335A3 (es) 2021-10-04
KR20220167340A (ko) 2022-12-20
AR112419A1 (es) 2019-10-30
IL271179A (en) 2020-01-30
KR102633368B1 (ko) 2024-02-06
AU2018284303A1 (en) 2019-11-07
JOP20190283A1 (ar) 2019-12-05
CO2019013838A2 (es) 2020-05-29
BR112019025904A2 (pt) 2020-06-30
AU2021206810A1 (en) 2021-08-12
WO2018229612A1 (en) 2018-12-20
TW201906864A (zh) 2019-02-16
MA49394A (fr) 2020-04-22
SG10201913536TA (en) 2020-02-27
MX2019015021A (es) 2020-02-24
TWI826377B (zh) 2023-12-21
RU2019140335A (ru) 2021-07-13
CR20190558A (es) 2020-01-28
US20190002589A1 (en) 2019-01-03
ZA201906757B (en) 2023-03-29
AU2018284303B2 (en) 2021-04-22
JOP20190283B1 (ar) 2023-09-17
CA3061097A1 (en) 2018-12-20
EP3638692A1 (en) 2020-04-22
JP2022116038A (ja) 2022-08-09
JP2020524991A (ja) 2020-08-27
KR20200005746A (ko) 2020-01-16
EA201992670A1 (ru) 2020-07-08

Similar Documents

Publication Publication Date Title
CL2019003613A1 (es) Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos.
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
MA55363A (fr) Anticorps multispécifiques egfr x cd28
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
CU24498B1 (es) Anticuerpos de factor xi
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
DK3797121T3 (da) Antistoffer, der er specifikke for CD3, og anvendelser deraf
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora